Uncategorized

Character Biosciences Raises $93 Million Series B to Advance Precision Medicine for Progressive Eye Diseases

by Business Wire • 2025/03/25 • 0 Comments

JERSEY CITY, N.J.--(BUSINESS WIRE)-- #AMD--Character Biosciences Raises $93 Million Series B to Advance Precision Medicine for Progressive Eye Diseases

← Alcon Announces CE Mark Approval and Commercialization of Clareon Vivity IOL in Europe, Expanding Visual Possibilities

Multiple Drug Classes Can Up Risk for Floppy Iris Syndrome →

Post navigation